Panorama
Moderna and Merck report success with mRNA vaccine against skin cancer
Moderna and Merck have announced positive results from a Phase III study of an mRNA vaccine against melanoma.
US pharmaceutical companies Moderna and Merck announced positive results from a clinical study of an mRNA vaccine against melanoma, commonly known as skin cancer, on Wednesday. This marks the first successful Phase III study of an mRNA-based cancer treatment.
According to the joint statement, the personalized vaccine reduces the risk of recurrence after surgical treatment of patients with advanced skin cancer. The results suggest that the vaccine may slow the spread of cancer to other areas of the body.
The study was part of the final phase of clinical trials, and the companies plan to submit applications for the vaccine's approval. This could represent a significant advancement in cancer treatment, especially for the patient population with melanoma.
The positive results have also impacted the stock prices of the companies involved, particularly Moderna's stock, which temporarily rose by 160 percent, indicating strong investor interest.
Experts and cancer research professionals have expressed their excitement over this development, which has the potential to revolutionize treatment approaches for patients with malignant skin conditions. Details regarding the study and its precise results have not yet been comprehensively released.
The testing companies, Moderna and Merck, have committed to providing further information on parts of the study to enhance understanding of the vaccine's effects and encourage potential future developments in cancer treatment.